Profit Pressure from Intensifying Price Competition in the Pharmaceutical Wholesale Market
First written in FY2017-Q3. 15 of 27 entries say "Worsened", first in FY2019-Q1. Latest entry: FY2027-H1.
Medical Ikkou Group moved to the "Worse" side of this theme in 2017.
0 other companies' latest entry also says "Restated".
- FY2027-H1RestatedAnnual report
「In the pharmaceutical wholesaling business, the challenging operating environment has continued due to rising cost ratios since April 2023.」
The company continues to describe the challenging earnings environment in the pharmaceutical wholesaling business caused by the rising cost ratio since April 2023. Meanwhile, operating income increased 66.3% year on year owing to contributions from existing locations and the 3 newly added companies. - FY2026WorsenedAnnual report
「In the pharmaceutical wholesale business, we are facing an earnings environment more challenging than that of the previous fiscal year.」
The impact of lower drug prices and the front-loading of integration costs made the earnings environment in the pharmaceutical wholesale business more challenging than in the previous year, and operating profit fell 16.7% year on year. - FY2026-H1WorsenedAnnual report
「The earnings environment has become more challenging due to the increase in the cost ratio continuing since April 2023. In addition, because integration costs were incurred ahead of the benefits, profit fell below the level of the same period of the previous year. As a result, revenue was ¥9,376 million, up 39.9% year on year, while operating profit was ¥89 million, down 53.9% year on year.」
In addition to the increase in the cost ratio since April 2023, the front-loading of integration costs meant that the pharmaceutical wholesale business achieved substantial revenue growth, while operating profit fell 53.9% year on year. - FY2025WorsenedAnnual report
「In the pharmaceutical wholesale business, the sharp increase in the cost ratio from April 2023 was followed by a further increase in costs during the second half of the fiscal year, leaving us facing an earnings environment more challenging than that of the previous fiscal year.」
The filing states that the increase in the cost ratio since April 2023 accelerated further in the second half of the fiscal year, making the earnings environment in the pharmaceutical wholesale business more challenging than in the previous year. - FY2025-H1RestatedAnnual report
「In the pharmaceutical wholesale business, the earnings environment has become even more challenging due to the sharp increase in the cost ratio since April of the previous year. To realize the benefits of the business integration completed in September 2023 between our core subsidiary 株式会社メディカル一光 and 西部沢井薬品株式会社, we focused on reviewing the organizational structure and strengthening sales capabilities.」
The filing continues to describe the challenging earnings environment caused by the increase in the cost ratio since April of the previous year. At the same time, the pharmaceutical wholesale business achieved higher revenue and profit through the post-integration review of the organizational structure and strengthening of sales capabilities. quantified is false, while materialized is true. - FY2025-Q1WorsenedAnnual report
「In the pharmaceutical wholesale business, the earnings environment has become even more challenging due to the sharp increase in the cost ratio since April of the previous year.」
The filing states that the earnings environment in the pharmaceutical wholesale business became even more challenging due to the sharp increase in the cost ratio since April of the previous year. - FY2024-Q3RestatedAnnual report
「In the pharmaceutical wholesale business, we have faced a sharp increase in the cost ratio since April 2023, and the earnings environment has changed completely. Under the current circumstances, it is difficult to maintain the same level of profit margin through an extension of our previous sales activities alone.」
The filing continues to state that the cost ratio rose sharply from April 2023 and that it remains difficult to maintain the same level of profit margin through previous sales activities alone. - FY2024-Q2WorsenedAnnual report
「In the pharmaceutical wholesale business, we have faced a sharp increase in the cost ratio since April 2023, and the earnings environment has changed completely. Under the current circumstances, it is difficult to maintain the same level of profit margin through an extension of our previous sales activities alone.」
In addition to drug price revisions and other factors, the cost ratio rose sharply from April 2023, making it difficult to maintain the same level of profit margin through previous sales activities alone. - FY2024-Q1WorsenedAnnual report
「However, since April, we have faced a sharp increase in the cost ratio, and the earnings environment is expected to become extremely challenging.」
In the pharmaceutical wholesale business, in addition to the previous profit pressure from drug price revisions, we have faced a sharp increase in the cost ratio since April, and the outlook is for the earnings environment to become even more challenging. - FY2023WorsenedAnnual report
「However, the earnings environment has become even more challenging due to the impact of drug price revisions.」
In the pharmaceutical wholesale business, the earnings environment became more challenging due to drug price revisions, and operating profit fell 49.6% year on year to ¥57 million. The risk has materialized as a decline in profit. - FY2023-Q3WorsenedAnnual report
「The earnings environment has become increasingly challenging due to the impact of drug price revisions, but we have worked to contain expenses through integrated business operations. As a result, revenue was ¥2,165 million, up 1.7% year on year, while operating profit was ¥28 million, down 60.1% year on year.」
The deterioration in the pharmaceutical wholesale business's earnings environment due to drug price revisions continued. Revenue increased, while operating profit fell 60.1% year on year. - FY2023-Q2WorsenedAnnual report
「Although the earnings environment has become increasingly challenging due to the impact of drug price revisions, the company has worked to contain expenses through integrated business operations. As a result, revenue was ¥1,402 million, down 1.5% year on year, and operating profit was ¥19 million, down 61.0% year on year.」
The impact of drug price revisions in the pharmaceutical wholesale market continued to pressure profit, and operating profit fell 61.0% year on year. - FY2021-Q3RestatedAnnual report
「There were no newly arising business or other risks during the cumulative consolidated period for the third quarter. Nor were there any material changes to the business or other risks described in the securities report for the previous fiscal year.」
No new risks or significant changes have arisen regarding profit pressure from intensifying price competition in the pharmaceutical wholesale market. - FY2021-Q2RestatedAnnual report
「There were no newly arising business or other risks during the cumulative consolidated period for the second quarter. Nor were there any material changes to the business or other risks described in the securities report for the previous fiscal year.」
No new risks or significant changes have arisen regarding profit pressure from intensifying price competition in the pharmaceutical wholesale market. - FY2020-Q3RestatedAnnual report
「There were no newly arising business or other risks during the cumulative consolidated period for the third quarter. Nor were there any material changes to the business or other risks described in the securities report for the previous fiscal year.」
No new risks or significant changes have arisen regarding profit pressure from intensifying price competition in the pharmaceutical wholesale market. - FY2020-Q2RestatedAnnual report
「There were no newly arising business or other risks during the cumulative consolidated period for the second quarter. Nor were there any material changes to the business or other risks described in the securities report for the previous fiscal year.」
No new risks or significant changes have arisen regarding profit pressure from intensifying price competition in the pharmaceutical wholesale market. - FY2019WorsenedAnnual report
「In the pharmaceutical wholesale business, revenue grew through active sales efforts, but profit declined due to the drug price revision implemented in April 2018 and intensifying price competition. As a result, revenue was ¥2,551 million, up 6.2% year on year, while operating profit was ¥39 million, down 66.0% year on year.」
Profit pressure from drug price revisions and intensifying price competition continued. Revenue increased, while operating profit fell 66.0%. - FY2019-Q3WorsenedAnnual report
「In the pharmaceutical wholesale business, revenue grew as a result of active sales efforts, but profit declined due to the drug price revision implemented in April 2018 and intensifying price competition. As a result, revenue was ¥1,869 million, up 4.8% year on year, and operating profit was ¥42 million, down 52.2%.」
Profit pressure from drug price revisions and intensifying price competition continued. Revenue rose 4.8% year on year, while operating profit fell 52.2%. - FY2019-Q2WorsenedAnnual report
「In the pharmaceutical wholesale business, revenue grew through active sales efforts, centered on Mie, Gifu, Shiga and Aichi prefectures, in response to the Ministry of Health, Labour and Welfare's measures to promote the use of generic drugs. However, profit declined due to the drug price revision implemented in April 2018 and intensifying price competition. As a result, revenue was ¥1,232 million, up 3.6% year on year, while operating profit was ¥32 million, down 49.9% year on year.」
Profit pressure from drug price revisions and intensifying price competition continued. Revenue rose 3.6% year on year, while operating profit fell 49.9%. - FY2019-Q1WorsenedAnnual report
「In the pharmaceutical wholesale business, revenue grew as a result of active sales efforts, mainly in Mie, Gifu, Shiga and Aichi prefectures, in response to the government's measures to promote the use of generic drugs. However, profit declined due to the drug price revision implemented in April 2018 and intensifying price competition. As a result, revenue was ¥626 million, up 5.5% year on year, and operating profit was ¥19 million, down 18.4%.」
Intensifying price competition and drug price revisions were again explicitly identified as sources of profit pressure. Revenue increased 5.5% year on year, while operating profit fell 18.4%. - FY2018DroppedAnnual report
「In the pharmaceutical wholesale business, we achieved higher revenue and profit as a result of active sales efforts, centered on Mie, Gifu, Shiga and Aichi prefectures, in response to the government's measures to promote the use of generic drugs.」
The filing's discussion of the pharmaceutical wholesale business states that revenue and profit increased, with no reference to the previously noted profit pressure from intensifying price competition. - FY2018-Q1MaterialisedAnnual report
「In the pharmaceutical wholesaling business, active sales activities mainly in Mie, Gifu, Aichi and Shiga prefectures resulted in higher revenue. Profit increased only slightly, affected by market conditions in which price competition was intensifying. As a result, revenue was ¥594 million, up 11.5% year on year, and operating profit was ¥24 million, up 4.3%.」
Intensifying price competition in the pharmaceutical wholesale market continued to pressure profit, and operating profit rose only slightly, up 4.3% year on year despite higher revenue. - FY2017-Q3First statedAnnual report
「Profit was affected by market conditions, where price competition continued to intensify. As a result, revenue was ¥1,641 million, up 53.4% year on year, while operating profit was ¥52 million, down 7.9% year on year.」
In the pharmaceutical wholesale business, intensified price competition materialized as pressure on profit, and operating profit fell 7.9% year on year despite higher revenue.